Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
FTH · NASDAQ · Pharmaceutical Preparations
Faeth Therapeutics (FTH) · oqro.io/stocks/FTH · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$10.03−0.62 (−5.82%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
No open-market purchase by an insider of Faeth Therapeutics was filed in the last 90 days. The latest on record was on Sep 11, 2023.
Since 2021, Faeth Therapeutics insiders reported 131 open-market purchases and 6 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2023.
No open-market sale by an insider of Faeth Therapeutics (FTH) was filed with the SEC in the last 90 days.
No trade in Faeth Therapeutics (FTH) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−31.0% (−$4.50) from Jun 16, 2026 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $14.53 on Jun 16, 2026 to $10.03 on Nov 13, 2026 (−31.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Austin, Tx.
Last 12 months
Not enough history
Market value
$259M
Short interest: 2.73M shares sold short (10.6% of shares outstanding), +17.7% vs the previous count, 6.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
−$43.3M
This quarter −$13M, a year earlier −$3.59M
Net debt
—
Debt —, cash $14.2M, at Sep 30, 2026
Net income, last 12 months
−$211M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Fund moves
4 tracked managers disclosed the same change for Q2 2026. Among this manager's largest new positions for Q2 2026.
Fund moves
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Fails to deliver: 75K shares (about $2.59M) were not delivered on time for settlement on Sep 21, 2026. SEC fails-to-deliver data.
Fails to deliver have many causes, including processing delays, and are often resolved within days.
0 active phase 3 trials and 2 active phase 2 trials led by this company, mostly in endometrial cancer, hr+ her2- breast cancer. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
Insiders of Faeth Therapeutics reported 131 open-market purchases and 6 sales since 2021; purchases in 3 different years, most recently 2023.
| Year | Bought | Sold |
|---|---|---|
| 2023 | $4K3×3 trades | $5.44M2×2 trades |
| 2022 | $2.91M58×58 trades | — |
| 2021 | $5.65M70×70 trades | $686K4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Last results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Not announced
Purchases after results
14%
13 of 91 insider purchases since 2021 came within 30 days after a results announcement
From Faeth Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Faeth Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
On the public record for Faeth Therapeutics over the 12 months to Nov 14, 2026: 2 clinical trials.